We are excited to announce that Biocytogen will be attending the Society of Toxicology’s (SOT) 65th Annual Meeting and ToxExpo in San Diego. Come explore the new methodologies and regulations that are reshaping the preclinical drug development process. Biocytogen’s pathology platform offers advanced toxicology, biomarker analysis, and histopathological evaluation across a variety of animal and disease models, so be sure to visit our booth #2145 and learn how we can help accelerate your drug discovery journey!
What is the SOT 65th Annual Meeting and ToxExpo?
The Society of Toxicology (SOT) is an organization of academic and professional scientists dedicated to advancing toxicology and advocating for a safer, healthier world. Its annual meeting brings together top researchers and industry experts to share the latest discoveries while fostering collaboration and promoting career growth. The program will consist of a vendor showcase with 250+ exhibitors, special lectures, and engaging workshops.
Event Overview
Date: March 22nd - 25th, 2026
Venue: San Diego Convention Center, 111 W. Harbor Drive, San Diego, CA 92101
Event Schedule
For more information, please refer to the event schedule.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to meeting you in San Diego, CA!
